TFPI2 Antibody, FITC conjugated

1. These results suggest that LSD2 achieves a promoting effect on small cell lung cancer by indirectly regulating TFPI2 expression through the mediation of DNMT3B expression or through the regulation of the demethylation of H3K4me1 in the promoter region of the TFPI2 gene. PMID: 29845195
2. MiR-616-3p binds specifically to the 3'-UTR region of TFPI2 mRNA. PMID: 30028057
3. Tissue factor pathway Inhibitor 2 potencies differ between antifibrinolytic agents against human and mouse enzymes plasmin, factor XIa, and kallikrein PMID: 27797450
4. estrogen induced TFPI-2 expression in MCF7 cells is mediated by ERalpha and also by the action of LSD1. PMID: 28088469
5. TFPI2 hypermethylation is associated with colorectal cancer. PMID: 28351398
6. our research indicated that miR-130a functions as an oncogene by targeting TFPI2, miR-130a inhibition reduced the growth and angiogenesis of hemangioma by inactivating the FAK/PI3K/Rac1/mdm2 pathway PMID: 28393235
7. TFPI-2 expression was decreased in bladder cancer. TFPI-2 expression was decreased with progression in tumor grade and stage and was correlated to decreased apoptosis. PMID: 28039717
8. TFPI2 is a useful serum biomarker for preoperative clinical diagnosis of CCC. PMID: 27798689
9. This TPR-dependent PP5 inhibition shown by Ro 90-7501 is a unique and novel inhibitory mechanism, which might be a useful tool for studies of PP5 on both regulatory mechanism and drug discovery. PMID: 27840051
10. Over-expression of TFPI-2 and aberrant promoter methylation status presented in the preeclampsia placentas, suggesting that epigenetic mechanism might contribute to the pathogenesis of preeclampsia. PMID: 28208084
11. Its methylation is a prognostic biomarker for hepatocellular carcinoma after hepatectomy. PMID: 26313014
12. Data show that silencing tumor-endothelial cells (EC) for trypsinogen 4 accumulated tissue factor pathway inhibitor-2 (TFPI-2) in the matrix. PMID: 26318044
13. Hypermethylation of TFPI2 promoter is increased in inflamed colon tissue. PMID: 25902909
14. DNA methylation of TFPI2 may play an important role in the carcinogenesis of cervical cancer and that the differential methylation of TFPI2 may at least partially explain the disparity in cervical cancer incidence between Uygur and Han women. PMID: 25973077
15. our findings suggested that the differential expression of MMP-2 and TFPI-2 have a negative correlation in pancreatic carcinoma PMID: 25755762
16. Our finding suggests that the decreased expression of TFPI-2 may play an important role in the carcinogenesis and progression, and may become a new adjunct marker in the diagnosis and prognosis in cholangiocarcinoma PMID: 25755719
17. TMPRSS4 is upregulated by silencing of TFPI-2 through aberrant DNA methylation and contributes to oncogenesis in non-small cell lung cancer. PMID: 25414083
18. TFPI-2 is a down-regulated tumor suppressor gene in oral squamous cell carcinoma, probably involving epigenetic silencing mechanisms. The loss of TFPI-2 expression is a key event for oral tumorigenesis, especially in the process of tumor metastasis. PMID: 25179542
19. regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 PMID: 25036127
20. TFPI-2 in platelets from normal or pregnant subjects and in plasma from pregnant women binds FV/Va and regulates intrinsic coagulation and fibrinolysis PMID: 25262870
21. TFPI-2 downregulation can contribute to tumor invasion of hepatocellular carcinoma cells through alteration in the expression of metastasis-related genes. PMID: 24591127
22. TFPI2 is a novel serum marker for ovarian clear cell adenocarcinoma and neoplastic transformation from endometriosis. PMID: 23805888
23. The present work demonstrated that the epigenetic inactivation of TFPI-2 by promoter hypermethylation was a frequent and tumor-specific event in glioblastoma, and TFPI-2 promoter methylation might be considered as a prognostic marker in glioblastoma. PMID: 23032906
24. Low or negative expression of TFPI-2 is associated with breast cancer progression, recurrence and poor survival outcome after breast cancer surgery. TFPI-2 expression in breast tumors is a potential prognostic tool for breast cancer patients. PMID: 23497249
25. The C-terminus of TFPI-2 encodes for antimicrobial activity, and may be released during wounding. PMID: 23300768
26. TFPI2 methylation in serum tended to be detected more easily in patients with advanced hepatocellular carcinoma (HCC) and might be used as a predictor of HCC progression. PMID: 23108564
27. TFPI-2 expression caused invasion and proliferation impair and induced apoptosis in TFPI-2 regulated BeWo and JEG-3 cells. It provides a clue for potential role of TFPI-2 in trophoblast. PMID: 22203034
28. TFPI-2 methylation is associated with non-small cell lung cancer. PMID: 21983100
29. There was a close association between the expression of tissue factor pathway inhibitor-2 (TFPI-2) and tumor cell apoptosis and angiogenesis in patients with cervical cancer. PMID: 22208663
30. Methylation was found in 28.2, 33.3 and 33.3% of grade 1, 2 and 3 esophageal dysplasia, and 67% of primary esophageal cancer, but no methylation was found in normal mucosa. PMID: 22449186
31. Results demonstrate the feasibility of using TFPI2 methylation and quantify human long DNA with fluorescent quantitative Alu PCR in fecal samples as a new noninvasive test for CRC. PMID: 21621497
32. recombined plasmid pEGFP-C1-TFPI-2 actually interacted with native RASSF1C PMID: 22232300
33. results confirm that detection of methylated TFPI2 in serum DNA was derived from colorectal cancer and could serve as a marker of surgical outcome PMID: 22399594
34. study provides evidence that inactivation of TFPI-2 synthesis might promote tumour invasion by a mechanism dependent on regulation of MMP-1, -2, -3, -7 and of ERK signalling pathway PMID: 20015200
35. Promoter hypermethylation of TFPI-2 is frequent and specific event in pediatric acute myeloid leukemia. PMID: 22052167
36. Serum TFPI2 methylation is associated with gastric cancer. PMID: 22110206
37. inverse expression of CD24 and TFPI-2 was observed by immunohistochemical analysis of primary breast cancers (N = 1,174). TFPI-2 expression was highest in CD24 negative samples and lowered with increasing CD24 expression PMID: 21984372
38. TFPI2 methylation was significant in the sera of patients with large, poorly differentiated carcinoma, deep invasion, lymph node metastasis, or distant metastasis. TFPI2 methylation was observed more frequently according to the progression of TNM stage. PMID: 21820798
39. Our findings underscore the important role of TFPI-2 as a tumor suppressor gene PMID: 21530612
40. Results showed that TFPI2 expression was not affected by with VLDL lipoproteins, but was induced by thrombin in THP-1 and monocyte-derived macrophages. PMID: 21515313
41. TFPI-2 plays a significant role in the growth, invasion, and metastasis of pancreatic carcinoma cell in vitro and in vivo, and has potential in anticancer therapy. PMID: 20018303
42. Epigenetic inactivation of TFPI-2 by promoter hypermethylation is a frequent and tumor specific event in nasopharyngeal carcinoma PMID: 21062455
43. Findings define a functional involvement for miR-616 and TFPI-2 in the development and maintenance of androgen-independent prostate cancer. PMID: 21224345
44. TFPI-2 plays a significant role in the invasion and metastasis of pancreatic carcinoma cell in vitro and in vivo. TFPI-2 is an independent prognostic factor for pancreatic carcinoma. PMID: 19763915
45. Aberrant methylation of the TFPI2 gene was detected in 7 out of 38 (18%) primary gastric carcinomas, suggesting that the methylation of TFPI2 is frequently observed in gastric carcinomas. PMID: 21036731
46. Placenta may be the main site of the high level of TFPI-2 production in maternal circulation PMID: 20347477
47. TFPI-2 influences smooth muscle cell proliferation and apoptosis in vitro in response to fluid shear stress. PMID: 20537494
48. these data indicate that TFPI-2 inhibits esophageal tumor invasion and angiogenesis both in vitro and in vivo. PMID: 20377370
49. TFPI2 may act as a tumour suppressor in colorectal carcinomas and TFPI2 methylation may present a potential risk of malignancy in colorectal cancer. PMID: 20530429
50. Expression, DNA methylation and histone modifications of TFPI2, a presumed tumor suppressor, and that of other genes in the 7q21 imprinted gene cluster in prostate cancer, were analysed. PMID: 20335518

Show More

Hide All

HGNC: 11761

OMIM: 600033

KEGG: hsa:7980

STRING: 9606.ENSP00000222543

UniGene: Hs.438231